ImmunoPharmaceutics Inc. said it has developed a new class oforally active compounds to treat hypertension.
The company said it believes the compounds, calledpeptidomimetics, are the first small molecules to be developedas antagonists of endothelin-1, a naturally occurring proteinthat raises blood pressure. IPI, which is 44 percent owned bySynbiotics Corp. (NASDAQ:SBIO), has filed for patents.
San Diego-based IPI plans to file an investigational new drugapplication in 1993 for one of the compounds.
The compounds were designed using the company's drugdesign process, which extracts three-dimensional templatesfrom pharmacologically active proteins or peptides. These arethen used to design orally active blockers of endothelin-1. IPIis also developing interleukin-1 receptor antagonists to treatinflammation.
(c) 1997 American Health Consultants. All rights reserved.